Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
460.00
+11.00 (2.45%)
At close: Dec 5, 2025
144.16%
Market Cap 107.27B
Revenue (ttm) 1.64B
Net Income (ttm) -791.34M
Shares Out 233.19M
EPS (ttm) -3.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 379,048
Average Volume 477,640
Open 449.00
Previous Close 449.00
Day's Range 447.40 - 462.60
52-Week Range 153.90 - 581.00
Beta 0.79
RSI 54.80
Earnings Date Nov 18, 2025

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally. Its product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC ta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 1,837
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6990
Full Company Profile

Financial Performance

In 2024, HKG:6990's revenue was 1.93 billion, an increase of 25.48% compared to the previous year's 1.54 billion. Losses were -266.77 million, -48.92% less than in 2023.

Financial numbers in CNY Financial Statements

News

Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up

(RTTNews) - Crescent Biopharma, Inc. (CBIO), on Thursday announced an exclusive partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics, i...

1 day ago - Nasdaq